Summary.
One main metabolizing pathway of levodopa is O-methylation to 3-O-methyldopa (3-OMD) by catechol-O-methyltransferase (COMT). Since COMT requires Mg2+ and S-adenosylmethionine as methyl donor for this transmethylating process, COMT converts S-adenosylmethionine to S-adenosylhomocysteine and subsequent homocysteine. Objective of this study was to demonstrate relations between plasma levodopa, 3-OMD and total homocysteine in treated parkinsonian subjects. We measured homocysteine, levodopa and 3-OMD by HPLC. We compared plasma homocysteine in two groups of treated parkinsonian subjects subdivided according to their 3-OMD level. Homocysteine was significantly (p = 0.002) elevated in the group with higher 3-OMD concentrations and positively (r = 0.52, p = 0.0006) correlated to 3-OMD. Homocysteine induces vascular disease. Previous studies showed an increase of ischaemic heart- and cerebrovascular disease in treated parkinsonian patients.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received November 20, 2000; accepted September 26, 2001
Rights and permissions
About this article
Cite this article
Müller, T., Woitalla, D., Fowler, B. et al. 3-OMD and homocysteine plasma levels in parkinsonian patients. J Neural Transm 109, 175–179 (2002). https://doi.org/10.1007/s007020200013
Issue Date:
DOI: https://doi.org/10.1007/s007020200013